Newsroom
Top Results
Event: Congress of German Ophthalmic Surgeons (DOC)
Event Details June 17-19 Nuremberg, Germany Contact Sight Sciences today to schedule a meeting.
Event: European Society of Cataract and Refractive Surgeons (ESCRS)
Event Details August 27-30 Amsterdam, Netherlands Contact Sight Sciences today to schedule a meeting.
Event: World Glaucoma Congress (WGC)
Event Details June 30- July 3 VIRTUAL Contact Sight Sciences today to schedule a meeting.
Event: European AECOS
Event Details June 3-6 Florence, Italy Contact Sight Sciences today to schedule a meeting.
Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial
Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing ab interno canaloplasty with selective laser trabeculoplasty. Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle […]
Sight Sciences Announces the Closing of its $7MM Series B Financing Led by Hicks Equity Partners
Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company today announced it has closed a $7 million Series B round of financing. The round was led by Hicks Equity Partners, a leading private equity firm based in Dallas, Texas. All Series A investors participated in the oversubscribed Series B round, including Scientific Health Development […]
Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include Anne-Marie Ripley, Vice President of Clinical and Regulatory Affairs, Ingrid Kane, M.D., Vice President of Global Medical Affairs, Jamie Chakales, Vice President of Global Sales […]
Sight Sciences Secures $10MM in Oversubscribed Series C Financing
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10 million Series C round of growth financing and strengthened its leadership team with a seasoned ophthalmic industry veteran. Allegro Investment Fund, a privately held fund based in Menlo Park, CA, led the round with full participation from all existing […]